Fundraising Fox
Eclipse Bio
San Diego, US · Founded 2017 · Delaware corporation · 42 employees on LinkedIn · 4 known investors
Find your way into Eclipse Bio
Sign up to see every warm intro you have to Eclipse Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eclipse Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
Founders & leadership
Eclipse Bio was founded in 2017 by Eugene Yeo.
Board
Investors · 4
How we know: iGlobe Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Phoenix Venture Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$16.9M disclosed across 2 rounds · 2021–2025
▶$4.9MraisedNov 2025 · 7 investors · BiotechnologyRule 506(b)
- Peter ChuExecutive Officer, Director
- Daniel VasellaDirector
- Edmond WongDirector
- Eugene YeoDirector
- Offering amount
- $7.2M
- Amount sold
- $4.9M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MraisedSep 2021 · 10 investors · BiotechnologyRule 506(b)
- Daniel VasellaDirector
- Peter ChuExecutive Officer, Director
- Eric L Van NostrandDirector
- Hallie KuhnDirector
- Eugene W YeoDirector
- Offering amount
- $15M
- Amount sold
- $12M
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Eclipse Bio.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $349.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.6M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Eclipse Bio do?
- Eclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
- Who founded Eclipse Bio?
- Eclipse Bio was founded by Eugene Yeo in 2017.
- Who are Eclipse Bio's investors?
- Eclipse Bio's investors include Brainstorm Ventures, iGlobe Partners, Magnetic Ventures, Phoenix Venture Partners.
- How much funding has Eclipse Bio raised?
- Eclipse Bio has disclosed $16.9M raised across 2 rounds.
- Where is Eclipse Bio headquartered?
- Eclipse Bio is headquartered in San Diego, US.